Menu

Press Releases

Date Summary View
Toggle Summary RedHill Biopharma Announces Presentation on YELIVA® (opaganib) for Multiple Myeloma at EORTC-NCI-AACR Symposium
TEL-AVIV, Israel and RALEIGH, N.C. , Nov. 14, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases and cancer, today ...
View HTML
Toggle Summary RedHill Biopharma Reports Third Quarter 2018 Financial Results and Business Highlights
Key Highlights: Top-line results from the confirmatory Phase III study with TALICIA ® for H. pylori infection are on track to be announced by year-end 2018, with potential NDA filing in early 2019 Positive top-line results from the Phase III study with RHB-104 for Crohn’s disease - the study ...
View HTML
Toggle Summary RedHill Biopharma to Host Third Quarter 2018 Financial Results Conference Call on November 13, 2018
TEL-AVIV, Israel and RALEIGH, N.C. , Nov. 06, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced ...
View HTML
Toggle Summary RedHill Biopharma to Host Analyst and Investor Webcast on TALICIA® for H. pylori infection on October 30, 2018
Top-line results from the ERADICATE Hp2 confirmatory Phase III study expected before year-end 2018 H. pylori bacterial infection affects over 50% of the adult population worldwide and 30-40% of the U.S. population TEL-AVIV, Israel and RALEIGH, N.C. , Oct. ...
View HTML
Toggle Summary RedHill Biopharma to Present at the BIO-Europe 2018 Conference
TEL-AVIV, Israel and RALEIGH, N.C. , Oct. 25, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced ...
View HTML
Toggle Summary RedHill Biopharma Announces Final Patient Assessed in Confirmatory Phase III Study with TALICIA® for H. pylori Infection
RedHill will host an Analyst and Investor Webcast on TALICIA ® for H. pylori infection on Tuesday, October 30, 2018 , at 8:30 a.m. EDT Final patient assessed for primary endpoint, with top-line results expected before year-end 2018   If successful, RedHill plans to file a U.S. ...
View HTML
Toggle Summary RedHill Biopharma Announces Additional Data from Positive Phase III Study of RHB-104 in Crohn’s Disease at United European Gastroenterology (UEG) Week 2018
The presentation highlighted enhanced p-values for previously reported outcomes, including the primary endpoint of clinical remission at week 26 (p=0.007) and key secondary and other efficacy endpoints of clinical response at week 26 (p=0.016), early clinical remission at week 16 (p=0.015), ...
View HTML
Toggle Summary RedHill Biopharma Late-Breaking Abstract on Positive Phase III Crohn’s Disease Study with RHB-104 to be Presented at UEG Week 2018
TEL-AVIV, Israel and RALEIGH, N.C. , Oct. 10, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced ...
View HTML
Toggle Summary RedHill Biopharma to Present at Ladenburg Thalmann 2018 Healthcare Conference
TEL-AVIV, Israel and RALEIGH, N.C. , Sept. 20, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced ...
View HTML
Toggle Summary RedHill Biopharma Announces Positive End-of-Phase II Meeting with FDA on BEKINDA® for IBS-D
The positive Type B meeting with the FDA followed a successful Phase II study of BEKINDA ® for diarrhea-predominant irritable bowel syndrome (IBS-D), one of the most common gastrointestinal disorders In light of the clarity provided by the FDA regarding the clinical and regulatory pathway for ...
View HTML